

Ana M Muoz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5848641/ana-m-munoz-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21
papers

633
citations

10
h-index

23
g-index

23
ext. papers

736
ext. citations

5.7
avg, IF

3.45
L-index

#	Paper	IF	Citations
21	Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. <i>Brain</i> , 2008 , 131, 3380-94	11.2	201
20	Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. <i>Experimental Neurology</i> , 2009 , 219, 298-307	5.7	79
19	Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. <i>Neuropharmacology</i> , 2006 , 51, 112-20	5.5	68
18	Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β. <i>Experimental Neurology</i> , 2014 , 261, 720-32	5.7	49
17	BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. <i>Experimental Neurology</i> , 2017 , 297, 73-81	5.7	41
16	Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia. <i>Molecular Neurobiology</i> , 2015 , 52, 1408-1420	6.2	36
15	Systemic administration of N-acetylcysteine protects dopaminergic neurons against 6-hydroxydopamine-induced degeneration. <i>Journal of Neuroscience Research</i> , 2004 , 76, 551-62	4.4	35
14	Glial overexpression of heme oxygenase-1: a histochemical marker for early stages of striatal damage. <i>Journal of Chemical Neuroanatomy</i> , 2005 , 29, 113-26	3.2	22
13	Physical Exercise Improves Aging-Related Changes in Angiotensin, IGF-1, SIRT1, SIRT3, and VEGF in the Substantia Nigra. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018 , 73, 1594-1601	6.4	21
12	Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson's Disease and Adverse Effects of L-DOPA. <i>Frontiers in Neuroanatomy</i> , 2020 , 14, 26	3.6	12
11	Fenfluramine-induced increase in preproenkephalin mRNA levels in the striatum: interaction between the serotonergic, glutamatergic, and dopaminergic systems. <i>Synapse</i> , 2000 , 35, 182-91	2.4	10
10	Aging-related Increase in Rho Kinase Activity in the Nigral Region Is Counteracted by Physical Exercise. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016 , 71, 1254-7	6.4	9
9	Effects of Rho Kinase Inhibitors on Grafts of Dopaminergic Cell Precursors in a Rat Model of Parkinson's Disease. <i>Stem Cells Translational Medicine</i> , 2016 , 5, 804-15	6.9	7
8	Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease. <i>British Journal of Pharmacology</i> , 2020 , 177, 5622-5641	8.6	7
7	Angiotensin AT and AT receptor heteromer expression in the hemilesioned rat model of Parkinson's disease that increases with levodopa-induced dyskinesia. <i>Journal of Neuroinflammation</i> , 2020 , 17, 243	10.1	7
6	Host brain regulation of dopaminergic grafts function: role of the serotonergic and noradrenergic systems in amphetamine-induced responses. <i>Synapse</i> , 2003 , 47, 66-76	2.4	6
5	Long-term cortical atrophy after excitotoxic striatal lesion: effects of intrastriatal fetal-striatum grafts and implications for Huntington disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001 , 60, 786-97	3.1	5

4	BDNF Overexpression Increases Striatal D3 Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1503-1514	5.3	5
3	Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists. <i>Frontiers in Neuroendocrinology</i> , 2021 , 62, 100914	8.9	5
2	GABAA receptor subunit expression in intrastriatal ventral mesencephalic transplants. <i>Experimental Brain Research</i> , 2000 , 135, 331-40	2.3	4
1	Novel Interactions Involving the Mas Receptor Show Potential of the Renin-Angiotensin system in the Regulation of Microglia Activation: Altered Expression in Parkinsonism and Dyskinesia. <i>Neurotherapeutics</i> , 2021 , 18, 998-1016	6.4	3